Divalproex Sodium Tablet, Delayed Release
Product Images NDC 57237-106

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 57237-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

This appears to be a figure from a study, showing the results of two different studies (Study 1 and Study 2). The abbreviations PBO, DVPK, P80, and DVPX are used, which may refer to different treatments or measurements used in the studies. There is a note that indicates that *p<0.05, which suggests that some statistical analysis has been done and there may be a significant difference between the groups shown in the figure.*

FDA Label Image

Figure 2 (Divalproex Fig2)

FDA Label Image

Figure 3 (Divalproex Fig3)

The text provides a graph showing the percentage reduction in CPS rate based on the dosage of a certain medication. The graph has two curves: High dose and low dose. The X-axis shows the percentage of patients, while the Y-axis indicates the level of improvement, no change, or worsening. However, there is no further information available to provide additional context.*

FDA Label Image

Figure 4 (Divalproex Fig4)

The text describes the mean 4-week migraine rates for Placebo and Divalproex Sodium in two different studies. The dose of Divalproex Sodium delayed-release tablets ranged from 500 to 1087 mg/day.*

FDA Label Image

Package Label-principal Display Panel (125 mg (100 Tablets Bottle))

This text describes the drug "Divalproex sodium USP" and its usual dosage as a delayed-release tablet. It also includes instructions for pharmacists to dispense the medication in a tightly sealed, light-resistant container and to check that the seal over the bottle is not broken or missing. The drug should be stored within the temperature range of 20 to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The text also provides a code and revision date for the full prescribing information.*

FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Each enteric-coated delayed-release tablet of Rising® (NDC 57237-047-01) contains 5 Divalproex Sodium USP equivalent to Valproic Acid 250 mg. Rising Health, LLC distributes Rising® from Saddle Brook, NJ 07663. Rising® is made in India and the usual dosage is dependent on prescribed guidelines enclosed in the full prescribing information with tablets, USP. Store Rising® between 20°C to 25°C (68°F to 77°F) and permit excursions between 15°C to 30°C (59°F to 86°F) to ensure maintained Valproic Acid activity. Rising® is to be dispensed by a pharmacist, who must verify a seal over the bottle and store it in a USP tight, light-resistant container. Rising® is available in 100 tablet bottles and the specification printing is permitted in a designated zone.*

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

FDA Label Image

Chemical Structure (Divalproex Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.